Merck Stock Top Executives

MRK Stock  USD 103.46  3.52  3.29%   
Merck employes about 67 K people. The company is managed by 55 executives with a total tenure of roughly 394 years, averaging almost 7.0 years of service per executive having 1218.18 employees per reported executive. Assessment of Merck management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Merck Company future performance.
Additionally, see Correlation Analysis.
  
  Kenneth Frazier  Chairman
Chairman of the Board, President, Chief Executive Officer
  Michael Rosenblatt  President
Executive Vice President Chief Medical Officer
  Mirian GraddickWeir  President
Executive Vice President - Human Resources

Merck Return on Sales

0.34

Merck Management Team Effectiveness

Merck Company has Return on Asset of 0.1268 % which means that on every $100 spent on asset, it made $0.1268 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.3815 %, implying that it generated $0.3815 on every 100 dollars invested. Merck management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Merck Return on Average Assets are increasing as compared to previous years. The last year's value of Return on Average Assets was reported at 11.91. The current Return on Average Equity is estimated to increase to 39.91, while Return on Investment is projected to decrease to 14.23. The current Tax Liabilities is estimated to increase to about 4.8 B, while Total Liabilities is projected to decrease to under 55.7 B.
Merck Weighted Average Shares is decreasing as compared to previous years. The last year's value of Weighted Average Shares was reported at 2.91 Billion. The current Weighted Average Shares Diluted is estimated to increase to about 3.2 B, while Issuance Purchase of Equity Shares is projected to decrease to (791.6 M).

Merck Workforce Comparison

Merck Company is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 315,124. Merck totals roughly 67,000 in number of employees claiming about 21% of equities under Health Care industry.

Merck Profit Margins

The company has Net Profit Margin of 0.26 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.35 %, which entails that for every 100 dollars of revenue, it generated 0.0 of operating income.

Merck Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Merck insiders, such as employees or executives, is commonly permitted as long as it does not rely on Merck's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Merck insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Merck Company Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Merck Company Price Series Division is a division of Merck price series and its benchmark/peer.
.

Merck Notable Stakeholders

A Merck stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Merck often face trade-offs trying to please all of them. Merck's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Merck's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kenneth Frazier - Chairman of the Board, President, Chief Executive OfficerProfile
Robert JD - Pres ChairmanProfile
Michael Rosenblatt - Executive Vice President Chief Medical OfficerProfile
Caroline Litchfield - Chief Financial Officer, Executive Vice PresidentProfile
Mirian GraddickWeir - Executive Vice President - Human ResourcesProfile
Julie Gerberding - Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population HealthProfile
Franklin Clyburn - President, Human Health, Head of Human Health Commercial and MarketingProfile
Robert Davis - Executive Vice President, Global Services, Chief Financial OfficerProfile
Steven Mizell - Executive Vice President, Chief Human Resources Officer, Human ResourcesProfile
Jim Scholefield - Executive Vice President, Chief Information and Digital OfficerProfile
Sanat Chattopadhyay - Executive Vice President and President - Merck Manufacturing DivisionProfile
Adam Schechter - President of Global Human Health and Executive VPProfile
Cristal Downing - Executive Vice President, Chief Communications, Public Affairs OfficerProfile
Jennifer Zachary - Executive Vice President, General Counsel, Corporate SecretaryProfile
Michael Holston - Executive Vice President Chief Ethics and Compliance OfficerProfile
Adele Ambrose - Senior Vice President Chief Communications OfficerProfile
Willie Deese - Executive Vice President and Presidentident - Merck Manufacturing DivisionProfile
Michael Nally - Executive Vice President, Chief Marketing OfficerProfile
Roger Perlmutter - Executive Vice President and Presidentident - Merck Research LaboratoriesProfile
Ashley Watson - Senior Vice President Chief Ethics and Compliance OfficerProfile
Richard DeLuca - Executive Vice President and Presidentident - Merck Animal HealthProfile
Frank Clyburn - Executive Vice President, Chief Commercial OfficerProfile
Clark Golestani - CIO and Executive VPProfile
Rita Karachun - Principal Accounting Officer, Sr. VP of Fin. and Global ControllerProfile
Rochelle Lazarus - Independent DirectorProfile
Paul Rothman - Independent DirectorProfile
Mary Coe - Independent DirectorProfile
Patricia Russo - Independent DirectorProfile
Robert Kidder - Independent DirectorProfile
Thomas Cech - Independent DirectorProfile
William Harrison - Lead Independent DirectorProfile
Thomas Glocer - Lead Independent DirectorProfile
Craig Thompson - Independent DirectorProfile
Christine Seidman - Independent DirectorProfile
Wendell Weeks - Independent DirectorProfile
Kathy Warden - Independent DirectorProfile
Peter Wendell - Independent DirectorProfile
John Noseworthy - Independent DirectorProfile
Leslie Brun - Lead Independent DirectorProfile
Inge Thulin - Independent DirectorProfile
Pamela Craig - Independent DirectorProfile
Carlos Represas - Independent DirectorProfile
Michael Fleming - Senior Vice President Chief Ethics and Compliance OfficerProfile
Jannie Oosthuizen - Lead - Human Health U.S.Profile
Jennifer Mauer - VP CommunicationsProfile
Michael Klobuchar - Executive Vice President Chief Strategy OfficerProfile
David Williams - Executive Vice President Chief Information Chief Information and Digital OfficerProfile
Lisa LeCointeCephas - Senior Vice President Chief Ethics and Compliance OfficerProfile
Deepak Khanna - Lead - Human Health InternationalProfile
Risa LavizzoMourey - Independent DirectorProfile
Arpa Garay - Lead - Human Health Global MarketingProfile
Joseph Romanelli - IR Contact OfficerProfile
Dean Li - Executive Vice President and Presidentident, Merck Research LaboratoriesProfile
Stephen Mayo - Independent DirectorProfile
Peter Dannenbaum - VP RelationsProfile

About Merck Management Performance

The success or failure of an entity such as Merck Company often depends on how effective the management is. Merck management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Merck management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Merck management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2023
Return on Investment 17.58  14.23 
Return on Average Assets 11.91  12.85 
Return on Average Equity 36.99  39.91 
Return on Invested Capital 0.30  0.25 
Return on Sales 0.34  0.30 
The data published in Merck's official financial statements usually reflect Merck's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Merck Company. For example, before you start analyzing numbers published by Merck accountants, it's critical to develop an understanding of what Merck's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Merck's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Merck's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Merck's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Merck Company. Please utilize our Beneish M Score to check the likelihood of Merck's management to manipulate its earnings.

Merck Workforce Analysis

Traditionally, organizations such as Merck use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Merck within its industry.

Merck Manpower Efficiency

Return on Merck Manpower

Revenue Per Employee591.2K
Revenue Per Executive885.5M
Net Income Per Employee186.3K
Net Income Per Executive237.3M
Working Capital Per Employee157.6K
Working Capital Per Executive192M
Today, most investors in Merck Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Merck's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Merck per employee as a starting point in their analysis.

Per Employee

Merck Per Employee Growth Over Time

Net Income Per Employee

186,342

Merck Net Income Per Employee is increasing as compared to previous years. The last year's value of Net Income Per Employee was reported at 172,707

Revenue Per Employee

591,215

Merck Revenue Per Employee is increasing as compared to previous years. The last year's value of Revenue Per Employee was reported at 644,612
Additionally, see Correlation Analysis. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for analysis

When running Merck Company price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.29) 
Market Capitalization
272.3 B
Quarterly Revenue Growth
0.137
Return On Assets
0.1268
Return On Equity
0.3815
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine Merck value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.